

RECEIVED

SEP 0 3 700.

**TECH CENTER 1600 2900** 



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Roger A. Sabbadini

Title:

COMPOSITIONS AND METHODS

FOR THE TREATMENT AND

PREVENTION OF

CARDIOVASCULAR DISEASES AND DISORDERS, AND FOR

**IDENTIFYING AGENTS** THERAPEUTIC THEREFOR

Appl. No.:

10/029,401

Filing

12/21/2001

Date:

Examiner:

Unknown

Art Unit:

1653

## INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.56

Commissioner for Patents **Box PATENT APPLICATION** Washington, D.C. 20231

Sir:

Applicant submits herewith on Form PTO-1449 a listing of the documents cited by or submitted to the U.S. PTO in parent application Serial No. 10/029372, filed 12/21/2001. As provided in 37 CFR §1.98(d), copies of the documents are not being provided since they were previously submitted to the United States Patent & Trademark Office in the above-identified parent application.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicant does not waive any rights to take any action

which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

## TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), before the mailing date of the first Office Action on the merits.

## **RELEVANCE OF EACH DOCUMENT**

The relevance of the foreign-language documents is explained in the parent application.

Applicant respectfully requests that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO-1449 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 50-0872. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 50-0872.



Atty. Dkt. No. 078853-0306

Respectfully submitted,

By /2. /2 / 12 /

Richard San Pietro Attorney for Applicant Registration No. 45,071

RECEIVED

SEP 0 3 Zam

TECH CENTER 1600 2900

**FOLEY & LARDNER** 

P.O. Box 80278

Facsimile:

(858) 792-6773

Sut. 23 2006

Page 1 of 21

Form PTO-1449 U.S. DEPARTMENT OF COMMERCE ATTY, DOCKET NO. SERIAL NO. PATENT AND TRADEMARK OFFICE (MODIFIED) 078853-0302 APPLICANT INFORMATION DISCLOSURE CITATION Roger A. Sabbadini FILING DATE **GROUP ART UNIT** several sheets if necessary) 12/21/2001 SEP 3 0 2007 **U.S. PATENT DOCUMENTS** XAMINER DOCUMENT FILING DATE SUB-DATE NAME CLASS MUTALEN IF **CLASS NUMBER APPROPRIATE** A1 6,210,976 04/03/2001 Sabbadini 5,929,039 07/27/1999 Woodcock, et al. A2 RECEIVED 5,677,288 10/14/1997 Marangos A3 SEP 0 3 7002 20010041688 11/15/2001 Waeber, et al. A4 4,150,949 04/24/1979 Smith A5 TECH CENTER 1600 2900 5,369,030 11/29/1994 Hannun, et al. A6 5,631,394 05/20/1997 Wei, et al. Α7 **FOREIGN PATENT DOCUMENTS** TRANSLATION **DOCUMENT** SUB-DATE COUNTRY CLASS REF NUMBER **CLASS** YES NO WO 98/57179 10/12/2000 PCT A33 WO 01/80903 11/01/2001 PCT A34 WO 99/12890 03/18/1999 PCT A35 Х WO 99/41266 08/19/1999 PCT A36 OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Abe, et al., "Glycosphingolipid depletion in Fabry disease lymphoblasts with potent inhibitors of A69 glucosylceramide synthase," Kidney International, 57:446-454 (2000) Abe, et al., "Structural and stereochemical studies of potent inhibitors and glucosylceramide synthase and A70 tumor cell growth," Journal of Lipid Research, 36:611-621 (1995) Abe, et al., "Use of Sulfobutyl Ether β-Cyclodextrin as a Vehicle for D-threo-1-Phenyl-2-decanoylamino-3morpholinopropanol-Related Glucosylceramide Synthase Inhibitors," Analytical Biochemistry, 287:344-347 A71 (2000)An, et al., "Characterization of a Novel Subtype of Human G Protein-coupled Receptor for Lysophosphotatidic A72 Acit," J. Biol. Chem., 273:7906-7910 (1998) An, et al., "Identification of cDNAs encoding two G protein-coupled receptors for lysosphingolipids," FEBS A73 Letts., 417:279-282 (1997) **EXAMINER DATE CONSIDERED** EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next

communication to applicant.

Page 2 of 21 Form PTO-1449 U.S. DEPARTMENT OF COMMERCE ATTY, DOCKET NO. SERIAL NO. (MODIFIED) PATENT AND TRADEMARK OFFICE 078853-0302 APPL NO02 **APPLICANT** INFORMATION DISCLOSURE CITATION Roger A. Sabbadini OIPE **FILING DATE GROUP ART UNIT** (Use several sheets if necessary) 12/21/2001 USPTO ART UNIT02 SEP 3 0 2002 **U.S. PATENT DOCUMENTS** EX**M**INER FILING DATE DOCUMENT SUB-DATE **CLASS** NAME 1F **CLASS** NUMBER **APPROPRIATE** 5,677,337 10/14/1997 **A8** Wei, et al. 11/27/2001 6,323,201 Carson, et al. Α9 RECEIVED 06/26/1990 4,937,232 Bell, et al. A10 SEP 0 3 2002 4,816,450 03/28/1989 Bell, et al. A11 5,331,014 07/19/1994 Kimura, et al. A12 TECH CENTER 1600/2900 08/11/1992 5,137,919 Igarashi, et al. A13 5,151,360 09/29/1992 Handa, et al. A14 A15 6,187,562 02/13/2001 Duckworth, et al. 5,851,782 12/22/1998 Hannun, et al. A16 5,079,263 01/07/1992 Zeeck, et al. A17 5,444,087 08/22/1995 Patel, et al. A18 6,284,798 09/04/2001 Amtmann, et al. A19 A20 6,306,911 10/23/2001 Wachter, et al. 6,051,598 04/18/2000 Shayman, et al. A21 A22 5,919,687 07/06/1999 Chatterjee 5,663,404 09/02/1997 Igarashi, et al. A23 5,260,288 11/09/1993 Igarashi, et al. A24 A25 5,391,800 02/21/1995 Igarashi, et al. 5,430,160 Boumendjel, et al. A26 04/04/1995 5,248,824 09/28/1993 Igarashi, et al. A27 5,912,144 06/15/1999 A28 Au-Young, et al. A29 6,130,067 10/10/2000 Tsui 6,057,126 05/02/2000 Munroe, et al. A30 5,585,476 12/17/1996 MacLennan, et al. A31 6,140,060 10/31/2000 Chun, et al. A32

Page 3 of 21

Form PTO-1449 U.S. DEPARTMENT OF COMMERCE ATTY. DOCKET NO. SERIAL NO. (MODIFIED) PATENT AND TRADEMARK OFFICE 078853-0302 APPL NO03 APPLICANT INFORMATION DISCLOSURE CITATION Roger A. Sabbadini OIPE FILING DATE **GROUP ART UNIT** 

(Use s	everal sheets if nece	ssary)		12/21/	2001	USPTO_	_ART_UN	IT03
SEP 3 0 2002 4		FOREIGN	I PAT	ENT DOCUMENTS	5			
SEP 3 0 2002 REF	DOCUMENT NUMBER	DATE		COUNTRY	CLASS	SUB- CLASS	TRANS	LATION
PADEM A37	WO 00/00593	01/06/2000	PCT				1.20	
A38	WO 00/21919	04/20/2000	PCT					
A39	Intentionally	Left	Blan	k	REC	EIVE		
A40	WO 00/52173	09/08/2000	PCT			3 2002		
A41	WO 00/58448	10/05/2000	PCT				<u> </u>	X
A42	WO 00/58491	10/05/2000	PCT		TECH CENT	<del>ER 1600/29</del>	<del>100 </del>	Х
A43	WO 00/59517	10/12/2000	PCT					
A44	WO 00/70028	11/23/2000	PCT					
A45	WO 00/72833 A2	12/07/2000	PCT				_	X
A46	WO 01/04108	01/18/2001	PCT					
A47	WO 01/04139	01/18/2001	PCT					
A48	WO 01/07418	02/01/2001	PCT					
A49	WO 01/31029	05/03/2001	PCT					
A50	WO 01/38295	05/31/2001	РСТ					Х
A51	WO 01/55410	08/02/2001	PCT				-	
A52	WO 01/57057	08/09/2001	РСТ					
A53	WO 01/60990	08/23/2001	PCT			-		
. A54	WO 01/72701	10/04/2001	PCT			-		_
A55	WO 01/85953	11/15/2001	PCT					
. A56	WO 97/44019	11/27/1997	PCT					
A57	WO 98/03529	01/29/1998	PCT					Х
A58	WO 98/28445	07/02/1998	PCT					
A59	WO 98/40349	09/16/1998	PCT					Х
A60	WO 99/07855	08/11/1998	РСТ					Х
A61	WO 99/12890	03/18/1999	PCT		-			Х
A62	WO 99/16888	04/08/1999	PCT					
A63	WO 99/33972	07/08/1999	PCT					
A64	WO 99/38983	08/05/1999	РСТ					
A65	WO 99/41265	08/19/1999	PCT					Х

Page 4 of 21 Form PTO-1449 U.S. DEPARTMENT OF COMMERCE ATTY. DOCKET NO. SERIAL NO. PATENT AND TRADEMARK OFFICE (MODIFIED) 078853-0302 APPL NO03 APPLICANT INFORMATION DISCLOSURE CITATION Roger A. Sabbadini **GROUP ART UNIT** FILING DATE (Use several sheets if necessary) 12/21/2001 USPTO\_ART\_UNIT03 SEP 3 0 2002 **FOREIGN PATENT DOCUMENTS** TRANSLATION DOCUMENT SUB-DATE COUNTRY CLASS NUMBER CLASS YES NO WO 99/41266 08/19/1999 PCT A66 WO 99/46277 09/16/1999 PCT A67 RECEIVED WO 99/61581 12/02/1999 PCT A68 \$EP 0 3 2002 TECH CENTER 1600/2900

Form PTO-1449	U.S. DEPARTMENT OF COMMERCE	ATTY. DOCKET NO.	Page 5 of 21 SERIAL NO.
(MODIFIED)	PATENT AND TRADEMARK OFFICE	078853-0302	APPL_NO04
		APPLICANT	
	ION DISCLOSURE CITATION	Roger A.	Sabbadini
OIPE		FILING DATE	GROUP ART UNIT
	everal sheets if necessary)	12/21/2001	USPTO_ART_UNIT04
SEP 3 0 2002 4	OTHER DOCUMENTS (Including A	Author, Title, Date, Pertinent Pag	ges, Etc.)
SEP 3 0 2002 4 A74	An, et al., "Sphingosine 1-phosphate-induby G protein-coupled receptors Edg3 and		
A75	Ancellin, et al., "Extracelluar export of spl the induction of angiogenic vascular mate M102841200).		
A76	Andrieu-Abadie, et al., "L-carnitine preveinhibition of ceramide generation," FASE		of cardiac myocytes: role of
A77	Arenz, et al., "Manumycin A and Its Anald ChemiBiochem., 2:141-143 (2001)	ogues Are Irreversible Inhibitors of	Neutral Sphingomyelinase,"
A78	Arenz, et al., "Synthese des ersten selek Chem., 112:1498-1500 (2000) (GERMAI		tralen Sphingomyelinase," <i>Angew</i>
A79	Arenz, et al., "Synthesis and Biochemical Sphingomyelinase," Bioorganic & Medicii	I Investigation of Scyphostatin Anal nal Chemistry, <u>9</u> :2901-2904 (2001)	ogues as Inhibitors of Neutral
A80	Arenz, et al., "Synthesis of the First Selection Chem., 137-140 (2001)	ctive Irreversible Inhibitor of Neutra	Sphingomyelinase," Eur. J. Org.
A81	Ariga, et al., "Role of Sphingolipid-mediat Research, 39:1-16 (1998)	ted cell death in neurodegenerative	diseases," Journal of Lipid
A82	Bajjalieh, et al., "Ceramide Kinase," Meth	ods in Enzymology, <u>311</u> :207-215 (	RECEIVE SEP 0 3 200
A83	Intentionally Left Blank		TECH CENTER 1600
A84	Intentionally Left Blank		
A85	Bawab, et al., "Molecular Cloning and Ch 275:21508-21513 (2000)	aracterization of a Human Mitochol	ndrial Ceramidase," J. Biol. Chem.,
A86	Bernardo, et al., "Purification and Charac Bovine Brain," <i>J. Biol. Chem.</i> , <u>275</u> :7641-7		ent Neutral Sphingomyelinase from
A87	Betto, et al., "Sphingosylphosphocholine sarcoplasmic reticulum membranes," <i>Bio</i>		calcium-release channel of cardiac
A88	Bielawska, et al., "(1S, 2R)-D-erhthro-2-(I Ceramidase," J. Biol. Chem., 271:12646-	N-Myristoylamino)-1-phenyl-1-propa 12654 (1996)	anol as an Inhibitor of

Form PTO-1449	U.S. DEPARTMENT OF COMMERCE	ATTY. DOCKET NO.	Page 6 of 21 SERIAL NO.
(MODIFIED)	PATENT AND TRADEMARK OFFICE	078853-0302	APPL NO04
		APPLICANT	
INFORMAT	TION DISCLOSURE CITATION	Roger A.	Sabbadini
OIPE		FILING DATE	GROUP ART UNIT
Dec :	several sheets if necessary)	12/21/2001	USPTO_ART_UNIT04
SEP 3 0 2002	OTHER DOCUMENTS (Including A	Nuthor, Title, Date, Pertinent Pag	ges, Etc.)
SEP 3 0 2002 &	Bielawska, et al., "Ceramide Is Involved i Reperfusion," <i>Am. J. Pathol.</i> , <u>151(5)</u> :125	n Triggering of Cardiomyocyte Apo 7-1263 (1997)	
A90	Boudker, et al., "Detection and Character Plasma Membrane," <i>J. Biol. Chem.</i> , 268:		Phosphatase Activity in Rat Lives
A91	Brady, et al., "The metabolism of sphin disease," <i>Proc. Natl. Acad. Sci. USA</i> , <u>55</u> (	gomyelin. II. Evidence of an enz 2):366-369 (1966)	ymatic deficiency in Niemann-Pick
A92	Brindley, et al., "Analysis of Ceramide 1-p Methods in Enzymology, 311:233-244 (19		sphate Phosphatase Activities,"
A93	Brownlee, C., "Intracellular signalling: sph (2001)	ningosine-1-phosphate branches o	ut," Current Biology, 11:R535-R538
A94	Burton, et al., "Human antibodies from co	mbinatorial libraries," Adv. Immuno	ol., <u>57</u> :191-280 (1994)
A95	Cain, et al., "Therapeutic Strategies to Re Ischemia and Reperfusion," J. Mol. Cell.		ntractile Depression Following
A96	Caligan, et al., "A High-Performance Liquand Related Compounds from Sphingosi Biochemistry, 281:36-44 (2000)	id Chromatographic Method to Me ne Kinase Assays and Other Biolog	asure Sphingosine 1-Phosphate gical Samples," <i>Analytical</i>
A97	Chan, et al., "Ceramide Path in Human L	ung Cell Death," Am. J. Respir. Ce	II Mol. Biol., <u>22</u> :460-468 (2000)
A98	Chan, et al., "Purification and Charac Biochemistry, <u>39</u> :4838-4845 (2000)	cterization of Neutral Sphingomy	yelinase from Helicobacter pylori,
A99	Chatterjee, "Neutral Sphingomyelinase,"	Advances in Lipid Research, <u>26</u> :25	5-49 (1993)
A100	Chatterjee, "Neutral Sphingomyelinase: past, present, and future," <i>Chemistry and Physics of Lipids</i> , 102:79-96 (1999)		
A101	Chatterjee, et al., "Molecular Cloning Sphingomyelinase," J. Biol. Chem., 274:3	, Characterization, and Express 7407-37412 (1999)	sion of a Novel Human Neutral
A102	Chau, et al., "Synthesis of Simple Aryl Ne (2001)	eutral Sphingomyelinase Inhibitors,	" Abstr. Pap. – Am. Chem. Soc.,
A103	Chun, "Lysophospholipid receptors: impli	cations for neural signaling," Crit. F	Rev. Neuro., 13(2):151-168 (1999)

			Page 7 of 21
Form PTO-1449	U.S. DEPARTMENT OF COMMERCE	ATTY. DOCKET NO.	SERIAL NO.
(MODIFIED)	PATENT AND TRADEMARK OFFICE	078853-0302	APPL_NO04
		APPLICANT	
INFORMAT	TION DISCLOSURE CITATION	Roger A. Sa	abbadini
IP F VC		FILING DATE	GROUP ART UNIT
(Use)	several sheets if necessary)	12/21/2001	USPTO_ART_UNIT04
CEP 3 0 DOOR OF	OTHER DOCUMENTS (Including A	uthor, Title, Date, Pertinent Pages,	
ERINZ IRANE MATO4	Chun, et al., "A Growing Family of Recep Lysophospholipids (LPs)," Cell Biochem.	tor Genes for Lysophosphatidic Acid (I & Biophys., 30:(2):213-242 (1999)	LPA) and other CH SEP
A105	Cordis, et al., "HPTLC analysis of sphing J. Pharm. And Biomed. Analysis, <u>16</u> :1189	pomylein, ceramide and sphingosine in 9-1193 (1998)	ischemic/reperfused heart,"
A106	Cuvlilier, et al., "Suppression of ceramide Nature, 381:800-803 (1996)	e-mediated programmed cell death by	sphingosine-1-phosphate,"
A107	Dickson, et al., "Serine Palmitoyltransfera	ase," Methods in Enzymology, <u>311</u> :1-9	(1999)
A108	Edsall, et al., <i>Biochem.</i> , "N,N-Dimethylsp not of protein kinase C: modulation of cel 12898 (1998)	hingosine is a potent competitive inhib lular levels of sphingosine 1-phosphat	itor of sphingosine kinase but e and ceramide," <u>37</u> :12892-
A109	Edson, et al., "The Aminoglycosides," Ma	yo Clin. Proc., <u>74</u> :519-528 (1999)	
A110	Eichler, et al., "Peptide, peptidomimetic, a <u>15</u> :481-496 (1995)	and organic synthetic combinatorial lib	raries," Med. Res. Rev.,
A111	Fensome, et al., "A Neutral Magnesium Membranes and Reversibly Inhibited by F		
A112	Fujii, et al., "Mg2+ binding and catalyti ( <i>Tokyo</i> ), <u>124</u> :1178-1187 (1998)	c function of sphingomyelinase from	Bacillus cereus," J. Biochem
A113	Fukushima, et al, "A single receptor enco cellular responses to lysophosphatidic ac	ded by <i>vzg-1/lp₄/edg-2</i> couples to G p id,"" <i>Proc. Natl. Acad. Sci.</i> , <u>95</u> :6151-61	roteins and mediates multple 56 (1998)
A114	Furneisen, et al., "Enzymological properti cerevisiae" <i>Biochim. Biophys. Acta.</i> , 1484		tase from Saccharomyces
A115	Garcia-Ruiz, "Human placenta sphingo induces oxidative stress, glutathione depl	mmyelinase, an exogenous acidic petion, and apoptosis in rat hepatocytes	oH-optimum sphingomyelinase, s," <i>Hepatology</i> , <u>32</u> :56-65 (2000)
A116	Gates, et al., "Serum amyloid p compor purified from the venom of the brown recl	nent: its role in platelet activation stin use spider (Loxosceles reclusa)," <i>Toxi</i>	nulated by sphingomyelinase d con, 28:1303-1315 (1990)
A117	Gatt, et al., "Niemann Pick disease: pres infantile form of the disease," J. Neuroche	sence of the magnesium-dependent spem., 31(2):547-550 (1978)	phingomyelinase in brain of the
A118	Gavrilenko, et al., "Nucleotide sequence cereus BKM-B164," <i>Bioorg. Khim.</i> , 19:133	e of phospholipase C and sphingor 3-138 (1993)	nyelinase genes from Bacillus

			Page 8 of 21
Form PTO-1449	U.S. DEPARTMENT OF COMMERCE	ATTY. DOCKET NO.	SERIAL NO.
(MODIFIED)	PATENT AND TRADEMARK OFFICE	078853-0302	APPL_NO04
		APPLICANT	
P ENFORMA	TION DISCLOSURE CITATION	Roger A	. Sabbadini
O' 4)		FILING DATE	GROUP ART UNIT
i vise	several sheets if necessary)	12/21/2001	USPTO_ART_UNIT04
EP 3 0 200 0	OTHER DOCUMENTS (Including A	Author, Title, Date, Pertinent Pa	ages, Etc.)
PADEMAR A119	Geeraert, et al., "Conversion of dihydro 327:125-132 (1997)	ceramide into ceramide: involve	ment of a desaturase," Biochem. J.
A120	Ghosh, et al., "Effects of gentamicin on s cells," <i>J. Biol. Chem.</i> , 262:12550-12556 (		ed human renal proximal tubular
A121	Ghosh, et al., "Identification, partial purification skeletal muscle: Neutral sphingomyelination."		
A122	Gilmore, et al., "A Bacillus cereus cytoly and sphingomyelinase genes: a nucleo (1989)		
A123	Glickman, et al., "Molecular Cloning, Tiss Nerve Growth Factor-Related G-Protein-		
A124	Goetzl, et al., "Eicosanoids and Other Bio Subfamily of G Protein-Coupled Cellular The Biochemistry and Biology of Lipid Ph	Receptors for Lysophospholipids	and Lysosphingolipids, Introduction
A125	Gonda, et al., "The novel sphingosine 1-pand -insensitive G-proteins to multiple sign		
A126	Gonzalez-Zorn, et al., "The smcL gene or bacterial escape from the phagocytic vac		
A127	Graler, et al., "EDG6, a Novel G-Protein- Lysophospholipids, Is Specifically Expres		
A128	Gunther, "Myocardial contractility after in <i>Pharma</i> ., 406:123-126 (2000)	nfarction and carnitine palmitoyltra	ansferase I inhibition in rats," Eur. J.
A129	Hakogi, et al., "Stereocontrolled synthe inhibitor," Org. Lett., 2:2627-2629 (2000)		ne analogue as a sphingomyelinas
A130	Hanada, et al., "Specificity of Inhibitors Biosynthesis, in Intact Cells," <i>Biochemica</i>		
A131	Hannun, et al., "Ceramide in the eukaryo	otic stress response," Cell Biology	v, <u>10</u> :73-80 (2000)
A132	Hannun, et al., "The Sphingomyelin Cycle 25:27-41 (1993)	e: A Prototypic Sphingolipid Signa	aling Pathway," Adv. Lipid Res.,

RECEIVED

SEP 03 491

Intentionally Left Blank

A133

				Page 9 of 21
Form PTO-1		U.S. DEPARTMENT OF COMMERCE	ATTY. DOCKET NO.	SERIAL NO.
(MODIFIED)		PATENT AND TRADEMARK OFFICE	078853-0302	APPL_NO04
			APPLICANT	
INF	ORMAT	ON DISCLOSURE CITATION	Roger A.	Sabbadini
OIPE	<u></u>		FILING DATE	GROUP ART UNIT
/0	( <b>G</b>	everal sheets if necessary)	12/21/2001	USPTO_ART_UNIT04
SEP 30	2002 E	OTHER DOCUMENTS (Including A	Author, Title, Date, Pertinent Pag	es, Etc.)
A MAD!	A 134	Hannun, et al., "Functions of Sphingolipic Science, 243:500-507 (1989)	ds and Sphingolipid Breakdown Pro	ducts in Cellular Regulation,"
	A135	He, et al., "A Fluorescence-Based High-F Cermidase Activity," <i>Analytical Biochemis</i>		y Assay to Determine Acid
	A136	Heringdorf, et al., "Stimulation of intracell sphingosine-1-phosphate receptors," Eur	ular sphingosine-1-phosphate prod c. J. Pharmacol., <u>414</u> :145-154 (2001	uction by G-protein-coupled )
	A137	Hernandez, et al., "Rapid Activation of Ne Myocytes," Circ. Res., 86:198-204 (2000)		a-Reoxygenation of Cardiac
	A138	Intentionally Left Blank		
~ <del></del>	A139	Hetland, et al., "Phospholipase C from Invest, 42(1):57-61 (1982)	Bacillus cereus has sphingomyel	inase activity," Scand J. Clin Lab
	A140	Higuchi, et al., "Acidic Sphingomyelinase Apoptosis and Nuclear Factor-κΒ Activati		
	A141	Hinkovska-Glacheva, et al., "Activation of Concomitant Ceramide Accumulation Du Leukocytes," <i>Blood</i> , <u>91</u> :4761-4769 (1998	ring IgC-Dependent Phagocytosis i	
	A142	Hise, et al., "Fatty Acyl Chain Compositio <u>77</u> (3):768-773 (1986)	n in the Determination of Renal Me	mbrane Oder," J. Clin. Invest.,
	A143	Hla, et al., "An Abundant Transcript Induction with Structural Similarities to G-Protein-co		
	A144	Hofmann, et al., "Cloning and charact sphingomyelinase," PNAS, 97:5895-5900	erization of the mammalian brain (2000)	-specific, Mg <sup>2+</sup> -dependent neutral
	A145	Hofstadler, et al., "Multiplexed Screening Electrospray Ionization FTICR MS: a Par 3440 (1999)	of Neutral Mass-Tagged RNA Tar adigm for High-Throughput Affinity	rgets against Ligand Libraries with Screening," Anal Chem., 71:3436-
	A146	Holopainen, et al., "Sphingomyelinase A Biol. Chem., <u>275</u> :16484-16489 (2000)	activity Associated with Human Pla	asma Low Density Lipoprotein," J.
	A147	Horn, et al., "Sphingofungins E and F: No J. Antibiot. (Tokyo), 45(10):1692-1696 (19		ibitors from Paecilomyces variotti,"
	A148	Hoye, et al., "Synthesis (and Alternative Fragment," <i>Organic Letters</i> , <u>2</u> :1481-1483	Proof of Configuration) of the Scyph (2000)	ostatin C(1) P(P) (Temple)

570 1110		T . == 0 = = =	Page 10 of 21
Form PTO-1449	U.S. DEPARTMENT OF COMMERCE	ATTY. DOCKET NO.	SERIAL NO.
MODIFIED)	PATENT AND TRADEMARK OFFICE	078853-0302 APPLICANT	APPL_NO04
INFORMAT	ION DISCLOSURE CITATION		. Sabbadini
OTPE		FILING DATE	GROUP ART UNIT
C',\	several sheets if necessary)	12/21/2001	USPTO ART UNIT04
SEP 3 0 ZUUZ Y	Hudson, "Recombinant antibody fragmen		-
A150	Humpf, et al., "Acylation of naturally occur Formation of N-palmitoyl-aminopentol pro category of ceramide synthase inhibitor,"	oduces a toxic metabolite of hydro	lyzed fumonisin, AP1, and a new
A151	Hunnan, "Functions of Ceramide in Coor (1996)	dinating Cellular Responses to St	ress," Science, <u>274</u> :1855-1859
A152	Igarashi, "Functional Roles of Sphingosir Membrane Sphingolipid Signaling Pathwa Molecule," <i>J. Biochem.</i> , 122:1080-1087 (	ays. 1. Sphingosine-1-Phosphate	Methylsphingosines: In Regard to as an Intercellular Signaling
A153	Igarashi, "Sphinosine-1-Phosphate as an Center, University of Washington, Seattle		F. Huchinson Cancer Research
A154	Ikezawa, et al., "Studies on Sphingomy Biophys Acta, 528(2):247-256 (1978)	relinase of Bacillus Cereus. I. Po	urification and Properties," Biochim
A155	Im, et al., "Molecular Cloning and Charac Prostate," <i>Molecular Pharmacology</i> , <u>57</u> :7	terization of a Lysophosphatidic A	Acid Receptor, Edg-7, Expressed in
A156	Im, et al., "Characterization of a novel spi 14286 (2000)	hingosine 1-phosphate receptor, E	Edg-8," <i>J. Biol. Chem.</i> , <u>275</u> :14281-
A157	Izuhara, et al, "Studies toward the Total S Cyclohexenone Segment," <i>Organic Lette</i>	Synthesis of Scyphostatin: First Er rs, 3:1653-1656 (2001)	ntry to the Highly Functionalized
A158	Jimbo, et al., "Development of a New (2000)	Inhibitor of Glucosylceramide Sy	nthase," J. Biochem., <u>127</u> :485-49
A159	Johansen, et al., "Bacillus cereus strain Acids Research, 16:10370 (1998)	SE-1: nucleotide sequence of the	sphingomyelinase C gene," Nucleio
A160	Jonghe, et al., "Structure-Activity Relation Kinase," Bioorganic & Medicinal Chemist		ses as Inhibitors of Sphingosine
A161	Kajstura, et al., "Apoptotic and Necrotic N Size in Rats," <i>Lab. Invest.</i> , <u>74</u> :86-107 (19		lent Contributing Variables of Infarct
A162	Kanfer, et al., "The Metabolism of Sphir enzyme from rat liver tissue," J. Biol. Che		perties of a sphingomyelin-cleaving
A163	Katircioglu, et al., "Myocardial preservation retroperfusion and carnitine," J. Cardiova	on in acute coronary artery occlusi sc. Surg., <u>41</u> :45-50 (1999)	on with cororan EnCEIVE

Form PTO-14	49	U.S. DEPARTMENT OF COMMERCE	ATTY. DOCKET NO.	Page 11 of 21 SERIAL NO.
MODIFIED)		PATENT AND TRADEMARK OFFICE	078853-0302	APPL_NO04
			APPLICANT	
INFO	RMAT	ION DISCLOSURE CITATION	Roger A.	Sabbadini
OF			FILING DATE	GROUP ART UNIT
615 4	Use s	everal sheets if necessary)	12/21/2001	USPTO_ART_UNIT04
SEP 3 0 2002	ين	OTHER DOCUMENTS (Including A	uthor, Title, Date, Pertinent Pa	ges, Etc.)
AL & TRADEN	164	Kay, et al., "Identification of enzyme inhib Chem. High Throughput Screen, 4:535-5		natorial peptide libraries," Comb.
	A165	Kester, "Sphingolipid Metabolites and the 9:447-460 (1997)	Cellular Phenotype," Trends in G	lycoscience and Glycotechnology,
	A166	Kihara, et al., "Direct Measurement of Ch and Reperfusion of the Intact Mammalian		
	A167	Kimura, et al., "Two Novel Xenopus Home Receptor Xenopus Oocytes and Mammal Manuscript MO11588200	ologs of Mammalian LPEDG-2 Fur ian Cells," JBC Papers in Press P	nction as Lysophosphatidic Acid ublished on-line 02/05/2001 as
	A168	Kita, et al., "Reverse hydrolysis reaction of a recombinant alkaline ceramidade of Pseudomonas aeruginos <i>Biochimica et Biophysica Acta</i> , 1485:111-120 (2000)		
	A169	Kohama, et al., "Molecular cloning and fu <i>Chem.</i> , <u>273</u> :23722-23728 (1998)	nctional characterization of murine	e sphingosine kinase," <i>J. Biol.</i>
	A170	Kolesnick, et al., "Characterization of a Separation From Diacylglycerol Kinase A		
	A171	Krown, et al., "Tumor necrosis factor alph sphingolipid signaling cascade in cardiac	a-induced apoptosis in cardiac my cell death," <i>J. Clin. Invest.</i> , <u>98</u> :285	ocytes. Involvement of the 54-2865 (1996)
	A172	Kubota, et al., "Accumulation of ceramide Japan J. Exp. Med., 59:59-64 (1989)	in ischemic human brain of an ac	ute case of cerebral occlusion,"
	A173	Kubota, et al., "Sphingomyelin changes ir (1996)	n rat cerebral cortex during focal is	chemia," <i>Neuro. Res.</i> , <u>18</u> :337-341
•	A174	Lanterman, et al., "Characterization of spl isolation of SK-deficient mutants," <i>Bioche</i>	hingosine kinase (SK) activity in S m. J., <u>332</u> :525-531 (1998)	accharomyces cerevisiae and
	A175	Lee, et al., "Improved Inhibitors of Glucos	ylceramide Synthase," J. Biol. Che	em., <u>274</u> :14662-14669 (1999)
	A176	Lee, et al., "Sphingosine 1-Phosphate Ind in Human Umbilical Endothelial Cells," <i>Bid</i>	luces Angiogenesis: its Angiogenic ochem Biophys Res. Commun., 26	c Action and Signaling Mechanism 64:743-750 (1999)
	A177	Lee, et al., "Lysophosphatidic acid and sp Am. J. Physiol. Cell Physiol., 278:C612-C		endothelial cell wound healing,"
	A178	Intentionally Left Blank		RECEIVE
				SEP 0 3 2001

Form PTO-1449		U.S. DEPARTMENT OF COMMERCE	ATTY. DOCKET NO.	Page 12 of 21 SERIAL NO.
(MODIFIED)	m	PATENT AND TRADEMARK OFFICE	078853-0302	APPL_NO04
	700		APPLICANT	
INEGE	MATE	ON DISCLOSURE CITATION	Roger A.	Sabbadini
	ינו		FILING DATE	GROUP ART UNIT
ER (	U <b>st</b> se	everal sheets if necessary)	12/21/2001	USPTO_ART_UNIT04
TRADEN	ř.	OTHER DOCUMENTS (Including A	uthor, Title, Date, Pertinent Page	es, Etc.)
SEP 3 0 2007	179	Lee, et al., "Cell-cycle-dependent change dephosphorylation in G2/M," Biochem. J.	s in ceramide levels preceding retino , <u>334</u> :457-461 (1998)	oblastoma protein
\$	180	Lee, et al., "Effect of Ischemia on Calciur Indo 1. Correlation with Monophasic Action	n-Dependent Fluorescence Transier on Potentials and Contraction," <i>Circ.</i>	nts in Rabbit Hearts Containing , <u>78</u> (4):1047-1059 (1988)
A	\181	Levade, et al., "Sphingomyelinases and N	Niemann-Pick disease," J. Clin. Cher	m. Biochem., <u>24</u> :205-220 (1986)
A	A182	Li, et al., "The Human Acid Ceramidase of and Expression," <i>Genomics</i> , <u>62</u> :223-231		omal Location, Mutation Analysis
A	\183	Liliom, et al., "Sphingosylphosphocholine in regulating cardiac function via sphingo		
A	\184	Lin, et al., "Identification of neutal and act 253 (1998)	dic sphingomyelinases in Helicobac	ter pylori, 5506 Con 423:340
Α	\185	Intentionally Left Blank		SEP 03 -
		-		TECH OFNIER HELD 2
A	A186	Linn, et al., "Regulation of de novo sphing Biochemical Society, pp. 831-835 (2001)		nsequences of its disruption,"
A	\187	Lister, et al., "Interaction of sphingomyeling positions of the sphingosine backbone," I		
Α	A188	Little, et al., "Surface display of antibodie	s," <i>Biotechn. Adv.</i> ., <u>12</u> :539-555 (1994	4)
A	\189	Liu, et al., "Molecular Cloning and Function Type 2 Isoform," <i>J. Biol. Chem.</i> , 275:195		mmalian Sphingosine Kinase
A	190	Liu, et al., "Purification and Character dependent and Phosphatidylserine-stimu 34479 (1998)	ization of a Membrane Bound No elated Sphingomyelinase from Rat E	eutral pH Optimum Magnesiun Brain," <i>J. Biol. Chem.</i> , <u>273</u> :34472
A	\191	Liu, et al., "Sphingomyelinase Assay Usir (2000)	ng Radiolabeled Substrate," Methods	s in Enzymology, <u>311</u> :164-167
А	192	Liu, et al., "Advances in the signal transdes Sci., 36:511-573 (1999)	uction of ceramide and related sphin	ngolipids," Crit. Rev. Clin. Lab.
А	193	Liu, et al., "Inhibition of the neutral magne 272:16281-16287 (1997)	esium-dependent sphingomyelinase	by glutathione," J. Biol. Chem.,

Form PTO-1449	U.S. DEPARTMENT OF COMMERCE	ATTY. DOCKET NO.	Page 13 of 21 SERIAL NO.
MODIFIED)	PATENT AND TRADEMARK OFFICE	078853-0302	APPL NO04
		APPLICANT	
INFORMAT	TION DISCLOSURE CITATION	Roger A. Sabbadini	
IPC		FILING DATE	GROUP ART UNIT
O To Ge	several sheets if necessary)	12/21/2001	USPTO_ART_UNIT04
SEP 3 0 2002	OTHER DOCUMENTS (Including A	outhor, Title, Date, Pertinent Pa	ges, Etc.)
AA94	Liu, et al., "Glutathione regulation of neut death," <i>J. Biol. Chem.</i> , 273:11313-11320	ral sphingomyelinase in tumor neo (1998)	crosis factor-alpha-induced cell
A195	Lochhead, et al, "Fluorinated anesthetic & Kidney Int., 54:373-381 (1998)	exposure "activates" the renal cort	ical sphingomyelinase cascade,"
A196	Luberto, et al., :Sphingolipid Metabolism	in the Regulation of Bioactive Mol	ecules," <i>Lipids</i> , <u>34</u> :S5-S11 (1999)
A197	Luberto, et al., "Sphingomyelin syntha diacylglycerol during SV40 transforma phosphatidylcholine-specific phopholipas	ation. Does sphingomyelin sy	nthase account for the putative
A198	Lynch, et al., "Life on the edg," Trends Pl	narmacol. Sci., <u>20</u> :473-475 (1999)	
A199	Magnelli, et al., "BCL-2 Overexpression A Murine," Bioch. Biophys. Res. Comm., 20	Abolishes Early Calcium Waving P 04:84-90 (1994)	receding Apoptosis in NIH-3T3
A200	Mandala, et al., "Isolation and Characte Viridiofungins, Rustmicin, and Khafrefung	rization of Novel Inhibitors of Sp gin," <i>Methods in Enzymology</i> , <u>311</u> :	hingolipid Synthesis: Australifungir 335-348 (1999)
A201	Mandala, et al., "Molecular cloning and he sphingosine-1-phosphate and induces ce		
A202	Mandala, et al., "Sphingosine-1-Phospha 156 (2001)	te Phosphatases," <i>Prostaglandins</i>	& Other Lipid Mediators, 64:143-
A203	Mandala, et al., "Inhibition of Serine Palr 379 (1994)	nityltransferase Activity by Lipoxa	mycin," <i>J. Antibiot. (Tokyo</i> ), <u>47</u> :376
A204	Mandala, et al., "Viridiofungins, Novel Ir (1997)	nhibitors of Sphingolipid Synthesi	s," J. Antibiot. (Tokyo), <u>50</u> :339-34
A205	Mandala, et al., "The Discovery of Austral Sporormiella australis. Producing Organis 48:349-356 (1995)		
A206	Mandala, et al., "Khafrefungin, a novel int	nibitor of sphingolipid synthesis," J	. Biol. Chem., <u>272</u> :32709-32714
A207	Mandala, et al., "Sphingoid base 1-phosp stress response," <i>Proc. Nat. Acad. Sci.</i> , 9	hate phosphatase: a key regulator <u>5</u> :150-155 (1998)	r of sphingolipid metabolism and
A208	Mao, et al., "Cloning and Characterization Hydrolyzes Phytoceramide," <i>J. Biol. Chem</i>		midase: A Mannellan Bazying Tha

			,	Page 14 of 21
Form PTO-1		U.S. DEPARTMENT OF COMMERCE	ATTY. DOCKET NO.	SERIAL NO.
(MODIFIED)	)	PATENT AND TRADEMARK OFFICE	078853-0302	APPL_NO04
			APPLICANT	
INF	ORMATI	ON DISCLOSURE CITATION		. Sabbadini
OIPE			FILING DATE	GROUP ART UNIT
		everal sheets if necessary)	12/21/2001	USPTO_ART_UNIT04
SEP 3 0 200	12 <sup>12</sup>	OTHER DOCUMENTS (Including A	Author, Title, Date, Pertinent Pa	nges, Etc.)
TRADEM	A209	Mao, et al., "Cloning and Characterization for Dihydroceramide," <i>J. Biol. Chem.</i> , 275		Alkaliine Ceramidase with Specificity
	A210	Mao, et al., "Cloning of an Alkaline Ceran (CoA-Independent) Ceramide Synthase A		
	A211	Mao, et al., "Molecular cloning and chaprotein from endoplasmic reticulum," Pro	aracterization of SCaMPER, a S oc. Natl. Acad. Sci. USA, <u>93</u> :1993-	phingolipid Ca2+ release-mediating 1996 (1996)
	A212	Marks, et al., "Methods for Studying Gluc	osylceramide Synthase," Methods	s in Enzymologyl, <u>311</u> :50-59 (1999)
	A213	Intentionally Left Blank		CERTY LA
	A214	Martin, et al., "Neutral Magnesium-Deper and Inhibition by Ubiquinol," <i>J. Bioenerg.</i>	ndant Sphingomyelinase from Live Biomember, <u>33</u> (2):143-153 (2001	er Plasma Meirito and Filiporification
	A215	Meacci, et al., "Receptor-mediated activa muscle C2C12 cells," FEBS Letters, 457:		gosine 1-phosphate in skeletal
	A216	Meldrum, "Tumor necrosis factor in the ho	eart," <i>Am. J. Physiol</i> ., <u>274</u> :R577-R	R595 (1998)
	A217	Melendez, et al., "Human sphingosine kir distribution," <i>Gene</i> , <u>251</u> :19-26 (2000)	nase: molecular cloning, functiona	I characterization and tissue
	A218	Meroni, et al., "Effect of N-Acetylsphingos myristoylamino)-1 phenyl-1-propanol on t 625 (1999)	sine (C2) and the Ceramidase Inh the Regulation of Sertoli Cell Fund	ibitor (1S,2R)-D-erythro-2-(N- tion," <i>Journal of Andrology</i> , <u>20</u> :619-
•	A219	Merrill, et al., "Activities of serine palmitoy different rat tissues," <i>J. Lipid Res.</i> , 26(5)		synthase) in microsomes from
	A220	Michel, et al., "Characterization of Cera TRANS-Double Bond of Sphingosine at the state of the s		
	A221	Mingeot-Leclercq, et al., "Aminoglycoside 43:727-737 (1999)	es: activity and resistance," Antimic	crobial Agents and Chemotherapy,
	A222	Mingeot-Leclercq, et al., "Aminoglycoside 1012 (1999)	es: nephrotoxicity," Antimicrobial A	gents and Chemotherapy, <u>43</u> :1003-
	A223	Mitsutake, et al., "Purification, Characteriz Ceramidase of Rat Kidney," J. Biol. Chen		bcellular Distribution of Neutral

Form PTO-1449	U.S. DEPARTMENT OF COMMERCE	ATTY, DOCKET NO.	Page 15 of 21 SERIAL NO.
(MODIFIED)	PATENT AND TRADEMARK OFFICE	078853-0302	APPL NO04
	7,772,774,677,62,774,677,62	APPLICANT	ATTI_NOOT
INFORMAT	ION DISCLOSURE CITATION		. Sabbadini
OIP E.		FILING DATE	GROUP ART UNIT
- URe s	several sheets if necessary)	12/21/2001	USPTO_ART UNIT04
SEB 3 0 5005			
	OTHER DOCUMENTS (Including A	Nuthor, Title, Date, Pertinent Pa	ges, Etc.)
THEDEMARY A224	Mohan, et al., "Evidence that Neutral Sph Externally on the Plasma Membrane," Bi		
A225	Mohler, et al., "Soluble Tumor Necrosis F Endotoxemia and Function Simultaneous 151(3):1548-1561 (1993)	actor (TNF) Receptors Are Effecti Sly as Both TNF Carries and TNF A	ve Therapeutic Agents in Lethal Antagonists," J. Immunol
A226	Nakajima, et al., " <i>Biophysical J.</i> , <u>78</u> :319	A (2000)	SEP 0 3 200%
A227	Napoli, et al., "Ischaemic preconditioning hypermaebility and microcirculatory dama		
A228	Nikolova-Karakashian, et al., "Ceramidas	es," Methods in Enzymology, 311	:194-201 (1999)
A229	Ohta, et al.," Induction of apoptosis by sp modulator of apoptotic DNA fragmentatio Res., 55:691-697 (1995)	phingosine in human leukemic HL- n occurring during phorbol ester-in	60 cells: a possible endogenous nduced differentiation," <i>Cancer</i>
A230	Ohta, et al., "A possible role of sphingosin neutrophils," FEBS Letters, 355:267-270		nor necrosis factor- $lpha$ in human
A231	Okamoto, et al., "EDG1 Is a Functional S Signaling Pathways, Including Phospoli Kinase Activation, and Adenylate Cyclase	pase C Activation, Ca <sup>2+</sup> Mobiliza	tion, Ras-Mitogen-activated Protei
A232	Okamoto, et al., "EDG3 Is a Ful Sphingosylphosphorylcholine with Sign. <i>Biophys. Res. Commun.</i> , <u>260</u> :203-208 (1	aling Characteristics Distinct fro	r Sphingosine 1-Phosphate an om EDG1 and AGR16," <i>Biochen</i>
A233	Okazaki, et al., "Characteristics and par sphingomyelinase activated in the early differentiation," <i>J. Biol. Chem.</i> , 269(6):40	signal transduction of $1\alpha,25$ -dihy	
A234	Okino, et al., "Molecular Cloning, Sequen from Pseudomonas aeruginosa: Cloning 274:36616-36622 (1999)	cing, and Expression of the Gene of A Ceramidase Homologue from	Encoding Alkaline Ceramidase mycobacterium Tuberculosis,"
A235	Olivera, et al., "Assaying Sphingosine Kir	nase Activity," Methods in Enzymon	logy, <u>311</u> :215-223 (1999)
A236	Olivera, et al., "Sphingosine-1-phosphate mitogens," <i>Nature</i> , 365:557-560 (1993)	as second messenger in cell proli	iferation induced by PDGF and FC
A237	Oral, et al., "Sphingosine mediates the im the adult mammalian cardiac myocyte," J		
A238	Oshefski, et al., "Glucosylceramide Syr Cancer, 93:131-138 (2001)	nthase Inhibition Enhances Vinci	ristine-Induced Cytotoxicity," Int.

SEP 3 0 2		ATTY DOOKET NO	Page 16 of 21	
orm PKQ-1449 MODIFIEO	U.S. DEPARTMENT OF COMMERCE	ATTY. DOCKET NO. 078853-0302	SERIAL NO.  APPL NO04	
PAGENT P		APPLICANT	APPII_NOU4	
INFORMAT	ION DISCLOSURE CITATION	Roger A. Sabbadini		
		FILING DATE	GROUP ART UNIT	
(Use s	everal sheets if necessary)	12/21/2001	USPTO_ART_UNIT04	
•	OTHER DOCUMENTS (Including A	Author, Title, Date, Pertinent Pa	ages, Etc.)	
· A239	Parrill, et al., "Identification of Edg1 Rece Chem., 275:39379-39384 (2000)	ptor Residues That Recognize Sp	phingozine 1-Phosphate," J. Biol.	
A240	Pitson, et al., "Human sphingosine kinase and recombinant enzymes," Biochem J.,	e: purification, molecular cloning a 350:429-441 (2000)	and characterization of the native	
A241	Pitson, et al., "Expression of a catalyticall sphingosine kinase activation. A dominar (2000)	ly inactive sphingosine kinase mu nt-negative sphingosine kinase," J	tant blocks agonist-induced  J. Biol. Chem 275:33945.33950  RECEIVE	
A242	Raag, et al., "Single-chain Fvs.," FASEB	J., <u>9</u> :73-80 (1995)	SEP 0 3 2002	
A243	Rani, et al., "Cell Cyle Arrest Induced by 2867 (1995)	an Inhibitor of Glucosylceramide	TECH CENTER 1600 2 Synthase," <i>J. Biol. Chem.</i> , <u>270</u> :2859	
A244	Riley, et al., "Fermentation, Partial Purification, an Use of Serine Palmitoyltransferase Inhibitors from <i>Isaria</i> (=Cordyceps) sinclairii," Methods in Enzymology, 311:348-361 (1999)			
A245	Romiti, et al., "Characterization of sphingomyelinase activity released by thrombin-stimulated platelets," <i>Molecular and Cellular Biochemistry</i> , 205:75-81 (2000)			
A246	Runcie, et al., "A Short andEfficient Route (2001)	e to Novel Scyphostatin Analogue	es," Organic Letters, <u>3</u> :3237-3239	
A247	Sabbadini, et al.," Sphingosine is endoge Comm.: 193:752-758 (1993)	nous to cardiac and skeletal mus	cle," Biochem. Biophys. Res.	
A248	Saint-Joanis, et al., "Gene cloning shows sphingomyelinase and lecithinase activities	the alpha-toxin of Clostridium peres," <i>Mol. Gen. Genet.</i> , 219(3):453	rfringens to contain both 3-60 (1989)	
A249	Saito, et al., "Absolute Configuration of So	cyphostatin," <i>Organic Letters</i> , <u>2</u> :50	05-506 (2000)	
A250	Sakai, et al., "A devise for recording left ventricular contraction and electrocardiogram in nonworking isolated perfused rat heart," <i>Jpn J. Pharmacol.</i> , 28:223-229 (1978)			
A251	Sato, "A new role of lipid receptors i Investigation, 6:939-940 (2000)	n vascular and cardiac morpho	ogenesis," The Journal of Clinica	
A252	Sawai, et al., "Function of the Cloned Phospholipase C," <i>J. Biol. Chem.</i> , 274(53	utative Neutral Sphingomyelinase ):38131-38139 (1999)	as Lyso-platelet Activating Factor	
A253	Sawai, et al., "Identification of ISC1 Saccharomyces cerevisiae," <i>J. Biol. Chem.</i>	(YER019w) as Inositol Phosph n., <u>275</u> :39793-39798 (2000)	osphingolipid Phospholipase C in	

SEP 3 0 20		ATTY DOCKET NO	Page 17 of 21	
orm P\$ 0-1449 MODIFIED)	US. DEPARTMENT OF COMMERCE	ATTY. DOCKET NO. 078853-0302	SERIAL NO.	
TRADE!	PATENT AND TRADEMARK OFFICE	APPLICANT	APPL_NO04	
	ION DISCLOSURE CITATION		. Sabbadini	
		FILING DATE	GROUP ART UNIT	
(Use s	everal sheets if necessary)	12/21/2001	USPTO_ART_UNIT04	
•	OTHER DOCUMENTS (Including A	Author, Title, Date, Pertinent Pa		
→ A254	Schissel, et al., "Zn2+-stimulated sphings sphingomyelinase gene," <i>J. Biol. Chem.</i> ,	omyelinase is secreted by many c 271:18431-18436 (1996)	ell types and is a product of the ad	
A255	Sergeyev, et al., "Lipid Spectrum of the Markosm. Med, 15:71-74 (1981)	Nyocardium of White Rats Expose	d to Hypoxic Hypoxia," Kosm. Biol	
A256	Shayman, et al., "Glucosylceramide Sy (1999)	nthase: Assay and Properties,"	Methods in Enzymology, 311:42-	
A257	Shayman, et al., "Inhibitors of Glucosylce	eramide Synthase," Methods in En	zymology, <u>311</u> :373-387 (1999)	
A258	Shinghal, et al., "Ceramide 1-Phosphate Phosphatase Activity in Brain," <i>Journal of Neurochemistry</i> , 61:2279 2285 (1993)			
A259	Siehler, et al., "Sphingosine 1-Phosphate Activates Nuclear Factor-kB through Edg Receptors: Activation Through Edg-3 and Edg-5, but not Edg-1, in Human Embryonic Kidney 293 Cells," JBC Papers in Press Published 10/22/2001 in Manuscript MO1107220			
A260	Siess, et al., "Lysophosphatidic Acid and Cardiovascular Diseases?" IUBMB Life, 4	Sphingosine 1-Phosphate: Two L 49:161-171 (2000)	ipid Villains Provoking	
A261	Smith, et al., "Hypoxia, calcium fluxes, ar 103(4):716-723 (1982)	nd inotropic state: Studies in cultur	ed heart cells," Amer. Heart J.,	
A262	Smith, et al., "Purified Fumonisin B1 Dec Capillary Permeability in Swine," <i>Toxicolo</i>			
A263	Spiegel, et al., "Sphingolipid metabolism	and cell growth regulation," FASE	B J., <u>10</u> :1388-1397 (1996)	
A264	Intentionally Left Blank			
A265	Spence, et al., "A new Zn2+-stimulated s 5363 (1989)	phingomyelinase in fetal bovine se	erum," <i>J. Biol. Chem.</i> , <u>264</u> (10):535	
A266	Spence, M.W., "Sphingomyelinases," Adv	v. Lipid Res., <u>26</u> :3-23 (1993)		
A267	Spiegel, et al., "REVIEW: Roles of Sphing Biochemistry (Moscow), 63:69-83 (1998)	gosine-1-phosphate in Cell Growth	n, Differentiation, and Death,"	
A268	Spiegel, et al., "Functions of a new family 1484:107-116 (2000)	of sphingosine-1-phosphate rece	ptors," Biochim Brooky Acre,	

0	IPE		(
SEP	3 0 <b>2002</b>	ريد و <sub>0</sub>	`

Page 18 of 21

orm (10-1449	₿.S. DEPARTMENT OF COMMERCE	ATTY. DOCKET NO.	Page 18 of 21 SERIAL NO.	
MODIFIED)	PATENT AND TRADEMARK OFFICE	078853-0302		
RADEMA	AT I ATENT AND INADEMARK OF ICE	APPLICANT	APPL_NO04	
INFORMATION DISCLOSURE CITATION		Roger A. Sabbadini		
		FILING DATE	GROUP ART UNIT	
(1150.5	everal sheets if necessary)	12/21/2001		
(036.3			USPTO_ART_UNIT04	
•	OTHER DOCUMENTS (Including A	Author, Title, Date, Pertinent Pa	ages, Etc.)	
▼ A269	Sucheck, et al., "Combinatorial synthesis (2001)	of aminglycoside libraries," Curr	Opin Drug Discov Devel., <u>4</u> :462-470	
A270	Sugita, et al., "Ceramidase and ceramide alkaline ceramidase," <i>Biochim. Biophys.</i>	e synthesis in human kidney and c Acta., 398:125-131 (1975)	cerebellum. Description of a new	
A271	Sugiyama, et al., "Sphingosine 1-phosph canine heart," <i>Cardiovasc. Res.</i> , <u>46</u> :119-	ate induces sinus tachycardia and 125 (2000)	d coronary vasoconstriction in the	
A272	Sumnicht, et al., "Lipid Composition of Tr Muscle," Arch. Biochem. Biophys., 215:6	ransverse Tubular Membranes fro 28-637 (1982)	m Normal and Dytophic Skeletal	
A273	Szulc, et al., "A facile regioselective synthesis of sphingosine 1-phosphate and ceramide 1-phosphate Tetrahedron Letter, 41:7821-7824 (2000)			
A274	Tamura, et al., "Mass production of sphingomyelinase of Bacillus cereus by a protein-hyperproducign strain Bacillus brevis 47, and its purification," <i>J. Biochem. (Tokyo)</i> , 112(4):488-491 (1992)			
A275	Tanaka, et al., "Structural Elucidation of Scyphostatin, an Inhibitor of Membrane-Bound Neutral Sphingomyelinase," <i>J. Am. Chem. Soc.</i> , <u>199</u> :7871-7872 (1997)			
A276	Tani, et al., "Purification and Characteriza Catalyzes the Reversible Reaction in Wh 275:3462-3468 (2000)	ation of a Neutral Ceramidase from hich Ceramide is Both Hydrolyzed	m Mouse Liver: A single Protein and Synthesized," <i>J. Biol. Chem.</i> ,	
A277	Tazabekova, et al., <i>Bioorg. Khim</i> , <u>13</u> :648	-653 (1987)		
A278	Tomita, et al., "Secondary structure of 108(5):811-815 (1990)	of sphingomyelinase from Bacil	lus cereus," J. Biochem. (Tokyo,	
A279	Tomiuk, et al., "Cloned mammalian neutr Acad. Sci. (USA), 95:3638-3643	ral sphingomyelinase: Functions i	n sphingolipid signaling?" Proc. Nat	
A280	Torley, et al., "A turbidometric assay for phospholipase C and sphingomyelinase," <i>Anal Biochem.</i> , 222:461-46 (1994)			
A281	Tosaka, et al., "Sphingosine 1-phosphate pathogenesis of cerebral vasospasm," St	e contracts canine basilar arteries troke, <u>32</u> :2913-2919 (2001)	in vitro and in vivo: possible role in	
A282	Triola, et al., "Synthesis of aCycloprop Desaturase," Angew. Chem. Int. Ed., 40:	ene Analogue of Ceramide, a I 1960-1962 (2001)	Potent Inhibitor of Dihydroceramid	
A283	Tsunoda, et al., "Early Fumonisin B1 Tox Mice," J. Biochem. Mol. Toxicol., 12:281-	icity in Relation to Disrupted Sphil 289 (1998)	ngolipid Matabalism in Mala BALB/o	

OIPE	45,00			
SEP 3 0 2007	<b>2</b>		Page 19 of 21	
Form (2) 0-1449	U.S. DEPARTMENT OF COMMERCE	ATTY. DOCKET NO.	SERIAL NO.	
(MODIFIED)	PATENT AND TRADEMARK OFFICE	078853-0302	APPL_NO04	
A DE VOEME		APPLICANT		
INFORMATI	ON DISCLOSURE CITATION	Roger A. Sabbadini		
		FILING DATE	GROUP ART UNIT	
(Use se	everal sheets if necessary)	12/21/2001	USPTO_ART_UNIT04	
•	OTHER DOCUMENTS (Including A	author, Title, Date, Pertinent Pages	s, Etc.)	
• A284	Uchida, et al., "Alutenusin, a Specific Neu 7436," <i>J. Antibiotics</i> , <u>52</u> (6):572-574 (199	utral Sphingomyelinase Inhibitor, Prod 9)	luced by Penicillium sp. FO-	
A285	Usta, et al., "Structural Requirements of Ceramidase," <i>Biochemistry</i> , 40:9657-966	Ceramide and Sphingosine Based Inh 8 (2000)	ibitors of Mitochondrial	
A286	Van Brocklyn, et al., "Sphingosine 1-phos the G protein-coupled receptor H218," J.	sphate-induced cell rounding and neur Biol. Chem., <u>274</u> :4626-4632 (1999)	rite retraction are mediated by	
A287	Van Veldhoven, "Sphingosine-1-phosphate Lyase" <i>Methods in Enzymology</i> , 311:244-254 (1999)			
A288	Van Veldhoven, et al., "Human sphingosi and mapping to chromosome 10q22 <sup>1</sup> ," <i>Bi</i>	ne-1-phosphate lyase: cDNA cloning, lochimica et Biophysica Acta, <u>1487</u> :12	functional expression studies 28-134 (2000)	
A289	Veldhoven, et al, "Sphingosine-Phosphat	e Lyase," <i>Adv. Lipid Res.</i> , <u>26</u> :69-98 (1	993)	
A290	Vivekananda, et al., "Sphingomyelin m cytidylyltransferase," <i>Am. J. Physiol. Lun</i> g	netabolites inhibit sphingomyelin syr g Cell Mol. Physiol., <u>2281</u> :L91-L107 (2	nthase and CTP:phophocholine	
A291	Walev, et al., "Selective killing of human monocytes and cytokine release provoked by sphingomyelinase (beta-toxin) of Staphylococcus aureus," <i>Infect. Immun.</i> , 64:2974-2979 (1996)			
A292	Wang, et al., "A Single Amino Acid Detern (EDG2) Phospholipid Growth Factor Reco M107301200			
A293	Wang & Merrill, et al., Adv. Lipid Res., 26	:215-234 (1993)		
A294	Winter, et al., "Making antibodies by phag	ge display technology," Annu. Rev. Im	munol., <u>12</u> :433-455 (1994)	
A295	Xia, et al., "High density lipoproteins (HDI mechanism for protection against atheros			

Xia, et al., "Tumor necrosis factor-alpha induces adhesion molecule expression through the sphingosine

Xu, et al, "Involvement of de novo ceramide biosynthesis in tumor necrosis factor-alpha/cycloheximide-induced cerebral endothelial cell death," *J. Biol. Chem.*, <u>273</u>:16521-16526 (1998)

Xu, et al., "Sphingosylphopsphorylcoline is a ligand for ovarian cancer G-protein-coupled receptor 1." Nature Cell Biology,  $\underline{2}$ :261-267 (2000)

kinase pathway," *PNAS*, <u>95</u>:14196-14201 (1988)

A296

A297

A298

/	<b>√</b> 0	I	P	E	8
PAT	SEP	3	0	2002	) e 60'.

(MODIRUSE) U.S. DEPARTMENT OF COMMERCE ATTY. DOCKET NO. PATENT AND TRADEMARK OFFICE

078853-0302 APPLICANT

Page 20 of 21 SERIAL NO.

APPL\_NO04

INFORMATION DISCLOSURE CITATION

Roger A. Sabbadini

INFORMATION DISCLOSURE CITATION		Roger A. Sabbadini					
		FILING DATE	GROUP ART UNIT				
(Us	se several sheets if necessary)	12/21/2001	USPTO_ART_UNIT04				
•	OTHER DOCUMENTS (Including	Author, Title, Date, Pertinent Pa	ges, Etc.)				
• A2	Yada, et al., "Purification and biochemic guinea pig skin," <i>J. Biol. Chem.</i> , <u>270</u> :12	cal characterization of membrane-bo 677-12684 (1995)	ound epidermal ceramidases from				
A30	Yamada, et al., "Nucleotide sequer sphingomyelinase of Bacillus cereus," E	Yamada, et al., "Nucleotide sequence and expression in Escherichia coli of the gene coding for sphingomyelinase of Bacillus cereus," <i>Eur. J. Biochem.</i> , <u>175(2)</u> :213-220					
A3(	Yamaji, et al., "Lysenin, a novel sphingo	omyelin-specific binding protein," J.	Biol. Chem., <u>273</u> :5300-5306 (1998)				
A36	Yamanaka, et al., "Acid Sphingomyelina 38:1753-1764 (1982)	ase of Human Brain: Purification to I	Homogeneity," J. Neurochem.,				
	Later Consult Later Charles		neoett				
A30	1) Intentionally Left Blank		SEP 0 3				
A36	Yamazaki, et al., <i>Biochem. Biophys. Re</i>	Yamazaki, et al., Biochem. Biophys. Res. Commun., 268:583-589 (2000)					
A30		Yatomi, et al., "Sphiongosine-1-Phosphate: A Platelet-Activating Sphingolipid Released from Agonist-Stimulated Human Platelets," <i>Blood</i> , <u>86</u> :193-202 (1995)					
A30	Yatomi, et al., "Sphingosine 1-phosphate, a bioactive sphingolipid abundantly stored in platelets, is a normal constituent of human plasma and serum," <i>J. Biochem.</i> , 121:969-973 (1997)						
A30	Yatomi, et al., "Sphingosine 1-phosphate induces platelet activation through an extracellular action and shares a platelet surface receptor with lysophosphatidic acid," <i>J. Biol. Chem.</i> , <u>272</u> :5291-5297 (1997)						
A30	Yellon, et al., " Ischaemic preconditionir (1992)	Yellon, et al., "Ischaemic preconditioning limits infarct size in the rat heart," Cardiovasc Res., 26:983-987 (1992)					
A30	Yoshimura, et al., "Inhibition of Neutral in Hypoxic PC12 Cell Death," <i>Journal of</i>	Yoshimura, et al., "Inhibition of Neutral Sphingomyelinase Activation and Ceramide Formation by Glutathione in Hypoxic PC12 Cell Death," <i>Journal of Neurochemistry</i> , 73:675-683 (1999)					
АЗ:	10 Intentionally Left Blank						
АЗ:		Zager, et al., "Decreased expression of mitochondrial-derived H2O2 and hydoxyl radical in cytoresistant proximal tubules," <i>Kidney Int.</i> , <u>52</u> :942-952 (1997)					
А3	Zechner, et al., "MKK6 inhibits myocard Chem., 273:8232-8239 (1998)	Zechner, et al., "MKK6 inhibits myocardial cell apoptosis via a p38 MAP kinase-dependent pathway," <i>J. Biol. Chem.</i> , 273:8232-8239 (1998)					
A3-	Zelinski, et al., "Phosphatidylcholine bi 11428 (1980)	osynthesis in isolated hamster hea	art," J. Biol. Chem., <u>255</u> (23):11423-				

6	2003 H	A314	Zhang, et al., "Human Acid Ceramidase Gene: Novel Mutations in Farber Disease," <i>Molecular Genetics and Metabolism</i> , 70:301-309 (2000)
ET SE	3 11 1000	A315	Zhang, et al., "Comparative analysis of three murine G-protein coupled receptors activated by sphingosine-1-phosphate," <i>Gene</i> , 227:89-99 (1999)
.ζ4	THADEN	A316	Zhou, et al., "Indentification of the First Mammalian Sphingosine Phosphate Lynase Gene and its Functional Expression in Yeast," <i>Biochem. Biophys. Res. Comm.</i> , 242:502-507 (1998)
	•	A317	Zweerink, et al., "Characterization of a Novel, Potent, and Specific Inhibitor of Serine Palmitoyltransferase," <i>J. Biol. Chem.</i> , <u>267</u> :25032-25038 (1992)

**RECEIVED** 

SEP 0 3 2001

TECH CENTER 1600-2900